Marked in vivo Donor Treg expansion via targeting of the IL-2/CD25 and TL1A/TNFRSF25 pathways ameliorates GVHD and preserves GVL

Authors :: Krishna V. Komanduri
Robert B. Levy
Eckhard R. Podack
Dietlinde Wolf
Sabrina Copsel
Cameron S. Bader
Henry Barreras
Casey O. Lightbourn
Brent J. Pfeiffer
Source :: Cytotherapy. 19:S11-S12
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Cancer Research
Transplantation
Oncology
Chemistry
In vivo
Immunology
Cancer research
Immunology and Allergy
Cell Biology
IL-2 receptor
Genetics (clinical)

Tools